Skip to main content
Fig. 5 | Clinical Proteomics

Fig. 5

From: Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases

Fig. 5

Primary melanoma cell cultures derived from cerebral metastases. Stratification of the samples by proliferation and viability assay and calculation of the IC50 for BRAF/MEK inhibitors (a). Sensitive cells show E-cadherin positivity and N-cadherin negativity in immunocytochemistry (b) and Western blot (c), whereas resistant cells show E-cadherin negativity and N-cadherin positivity

Back to article page

Clinical Proteomics

ISSN: 1559-0275